Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial

Table 5 Follow-up evaluations

	Before Treatment	Year 1^a	Year 2–5^a
History and Physical	X	3, 6, 9, 12 mo	18 mo, 24 mo, then annually
Assessment by Respirology/Pulmonology	X	At least every 6 months	At least annually
Central review of ILD diagnosis	X
PET/CT	X
Brain MRI	If symptoms (see Pre-treatment Evaluation)
Mediastinal staging	Optional (see Pre-treatment Evaluation)
HRCT chest	X	3, 6, 12 mo	18 mo, 24 mo, then annually
PFTs^b	X	6, 12 mo	18 mo, 24 mo, then annually
Toxicity Scoring	X	3, 6, 9, 12 mo	18 mo, 24 mo, then annually
FACT-L, EQ-5D-5L QOL scoring and cough severity scale	X	3, 6, 9, 12 mo	18 mo, 24 mo, then annually

^aAll times are measured from end of radiation
^bTo avoid duplication of PFTs, if the patient is having PFTs done by other physicians (e.g. respirologists), the PFTs must only be +/− 2 months of the dates stated above to be acceptable

ISSN: 1471-2407